How do you treat patients with stage III squamous cell carcinoma of the lung with persistent/progressive disease despite concurrent chemoradiation?   

In patients with persistent disease without true radiographic progression outside the radiation fields, proceeding with consolidation durvalumab per the PACIFIC trial is reasonable. The robust benefits of durvalumab in the PACIFIC trial were likely from treatment of both persistent and micrometastat...